Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆
Title:
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆
Author:
Lorusso, D. Colombo, N. Dubot, C. Cáceres, M.V. Hasegawa, K. Shapira-Frommer, R. Salman, P. Yañez, E. Gümüş, M. Olivera, M. Samouëlian, V. Castonguay, V. Arkhipov, A. Li, K. Toker, S. Tekin, C. Tewari, K.S. Monk, B.J.
Appeared in:
Annals of oncology
Paging:
Volume 36 () nr. 1 pages 65-75
Year:
2025
Contents:
Publisher:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., The Author(s)